Appendix 1: The following tables extract from the Federal Register is included as references for the measure reporting requirements.

TABLE 16: Requirements for Successful Reporting of ESRD QIP Reporting Measures for PY 2027

Measure	Reporting Frequency	Data Elements

MedRec	Monthly	• Date of the medication reconciliation.
		• Type of eligible professional who completed the medication reconciliation:
		  o physician,
		  o nurse,
		  o advanced registered nurse practitioner (ARNP),
		  o physician assistant (PA),
		  o pharmacist, or
		  o pharmacy technician personnel
		• Name of eligible professional

Hypercalcemia	Monthly	Total uncorrected serum or plasma calcium lab values
COVID-19 Vaccination Coverage Among HCP	At least one week of data each month, submitted quarterly	Cumulative number of HCP eligible to work in the facility for at least one day during the reporting period and who are up to date on their COVID-19 vaccination.
Facility Commitment to Health Equity	Annually	Domains to which facility must attest affirmatively: • Equity is a Strategic Priority • Data Collection • Data Analysis • Quality Improvement • Leadership Engagement
Screening for Social Drivers of Health	Annually	Number of eligible patients who were screened for all five HRSNs: • Food insecurity, • Housing instability, • Transportation needs, • Utility difficulties, or • Interpersonal safety.
Screen Positive Rate for Social Drivers of Health	Annually	Number of eligible patients with 'Yes' or 'No' (non-missing) screening responses for each of the five HRSNs.

6. Eligibility Requirements for the PY 2027 ESRD QIP

In the proposed rule, we proposed to update eligibility requirements as part of our proposal to replace the Kt/V Dialysis Adequacy Comprehensive clinical measure with a Kt/V Dialysis Adequacy Measure Topic beginning with PY 2027 (89 FR 55819). Our previously finalized and proposed new minimum eligibility requirements are described in Table 16 of the CY 2025 ESRD PPS proposed rule (89 FR 55820) and provided in Table 17 of this final rule.